2_SAGE_Appendicies_Background_final

Appendix A6C.1 Vaccine Hesitancy Landscape AnalysisVaccine Hesitancy Landscape AnalysisBackground:List of key players working on the issue of Vaccine Hesitancy §SAGE Working Group on Vaccine HesitancyJuly 2014Vaccine hesitancy is one of several concepts and ideas that relate to the demand side of vaccine usage.Vaccine hesitancy is an emerging term in the discourse on determinants of vaccine acceptance where uptake of avaccine or immunization programme in a community is lower than would be expected in the context ofinformation given and services available. Vaccine hesitancy is influenced by a complex network of factors includingissues of complacency, convenience and/or confidence in vaccine(s) or immunization programme that may resultin refusal, delay or uncertainty towards some or all vaccines. These factors which influence vaccine acceptancevary by setting and responses need to be locally assessed.This landscape analysis attempts to take a relatively broad view of vaccine hesitancy by including actorsworking on the issue. The purpose of this document is to stimulate a continuous compilation of organizationsinvolved in vaccine hesitancy work. The intention is that the list becomes more populated and evergreen asstakeholders, organizations, institutes and communities respond with suggested additions. This regularly updatedresource could be presented in form of a wiki approach in order to foster collaboration between the differentplayers in the field of vaccine hesitancy.Objectives:• Allow to identify what organisations are working on the issue of vaccine hesitancy in varioussettings/countries.• Allow those working on the issue of vaccine hesitancy to identify potential partners, donors and collaboratorsin the field.• Allow people to identify the regions where work is being done on vaccine hesitancy and what kind of work isbeing done in each area.• Be a regularly updated resource on work currently being done in the field of vaccine hesitancy• Help identify research and funding gaps—particularly in countries where there are more significant vaccinehesitancy issues.Methods:§ No claims can be made about the completeness or adequacy of the contents of this document .92